Working… Menu

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) (LUPIL-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02955615
Recruitment Status : Completed
First Posted : November 4, 2016
Last Update Posted : March 5, 2019
Information provided by (Responsible Party):
Iltoo Pharma

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : August 27, 2018
Actual Study Completion Date : February 11, 2019